Search

Your search keyword '"Kawagoe H"' showing total 4 results
Start Over Author "Kawagoe H" Topic leukemia, myeloid
4 results on '"Kawagoe H"'

1. TEL2, an ETS factor expressed in human leukemia, regulates monocytic differentiation of U937 Cells and blocks the inhibitory effect of TEL1 on ras-induced cellular transformation.

Author

Kawagoe H, Potter M, Ellis J, and Grosveld GC

Subjects
Animals, Calcitriol antagonists & inhibitors, Calcitriol pharmacology, Cell Differentiation drug effects, Cell Differentiation physiology, DNA-Binding Proteins antagonists & inhibitors, DNA-Binding Proteins biosynthesis, DNA-Binding Proteins genetics, Gene Expression Regulation, Leukemic, Hematopoietic Stem Cells pathology, Hematopoietic Stem Cells physiology, Humans, Leukemia, Myeloid genetics, Leukemia, Myeloid metabolism, Mice, Monocytes pathology, Mutation, NIH 3T3 Cells, Proto-Oncogene Proteins c-ets, RNA, Messenger biosynthesis, RNA, Messenger genetics, Repressor Proteins antagonists & inhibitors, Repressor Proteins biosynthesis, Repressor Proteins genetics, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors biosynthesis, Transcriptional Activation, Transfection, U937 Cells, Up-Regulation, ras Proteins genetics, ETS Translocation Variant 6 Protein, Cell Transformation, Neoplastic pathology, DNA-Binding Proteins physiology, Hematopoietic Stem Cells cytology, Leukemia, Myeloid pathology, Monocytes cytology, Repressor Proteins physiology, Transcription Factors physiology, ras Proteins physiology
Abstract

TEL2 is a member of the ETS family of transcription factors, which is highly similar to TEL1/ETV6. It binds to DNA via the ETS domain and interacts with itself or TEL1 via the pointed domain. The expression of TEL2 in normal and leukemic hematopoietic cells suggests a role in hematopoietic development. In this article, we describe the role of TEL2 in hematopoietic differentiation and cellular transformation. Quantitative reverse transcription-PCR showed that the expression of TEL2 mRNA was down-regulated during monocytic differentiation of U937 and HL60 induced by 1,25-(OH)2 vitamin D3 and 12-O-tetradecanoylphorbol 13-acetate, respectively. Overexpression of TEL2 in U937 cells inhibited differentiation induced by vitamin D3. In contrast, overexpression of a TEL2 mutant lacking either the pointed domain or a functional ETS domain induced both differentiation of U937 cells and inhibited their growth in vitro and in vivo. In addition, these mutants blocked TEL2-mediated transcriptional repression of a synthetic promoter containing TEL2 binding sites. These data suggest that dominant-negative inhibition of TEL2 might cause differentiation. Quantitative reverse transcription-PCR demonstrated that TEL2 is expressed at higher level in some primary human leukemia samples than in normal bone marrow. Furthermore, overexpression of TEL2 in NIH3T3-UCLA cells blocked the inhibitory effect of TEL1 on Ras-induced cellular transformation. These results suggest that TEL2 may play an important role in hematopoiesis and oncogenesis.

Published
2004
Full Text
View/download PDF

3. [Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].

Author

Masaoka T, Kimura K, Miyazaki T, Sakurada K, Saitoh H, Morioka M, Fujimoto N, Musashi M, Wakui A, Yokoyama M, Kanamaru R, Oguro M, Takagi T, Konda C, Saitoh T, Nakao I, Harashima S, Ohhashi Y, Sakai Y, Sasaki T, Ohno R, Katoh Y, Yamada K, Hirota Y, Takada T, Hoshino A, Ohara K, Kamiya O, Kojima T, Nagata K, Nakamura T, Sasada M, Yonezawa T, Tsubakio T, Kanayama Y, Kitani T, Taniguchi N, Yasunaga K, Okamoto Y, Fujitake H, Ohkubo A, Horiuchi A, Tsubaki K, Takubo T, Shibata H, Kawagoe H, Hirata M, Matsubuchi T, Nagai K, and Fujita S

Subjects
Adult, Aged, Clinical Trials as Topic, Female, Humans, Leukemia, Myeloid, Acute drug therapy, Male, Middle Aged, Nitrosourea Compounds adverse effects, Leukemia, Myeloid drug therapy, Lymphoma drug therapy, Multiple Myeloma drug therapy, Nitrosourea Compounds therapeutic use
Abstract

A total of 117 cases with hematological malignancies were treated with MCNU at doses of 70-100 mg/m2. Following are the results obtained. 1. MCNU showed a marked depression of cells in the cases with CML, polycythemia vera and thrombocythemia. The low level of cells was maintained for 2 to 7 months. 2. A good response was observed in several cases with blastic crises of CML. 3. No response was observed in two cases with acute leukemia. 4. Although a fair response was observed in several cases with malignant lymphoma or multiple myeloma, moderate bone marrow suppression was observed in a majority of the cases.

Published
1983

4. A new nitrosourea derivative for the treatment of chronic myelogenous leukemia.

Author

Hiraoka A, Masaoka T, Shibata H, Miyazaki T, Nakamura T, Yasunaga K, Kitani T, Yonezawa T, Kawagoe H, and Horiuchi A

Subjects
Adult, Aged, Antineoplastic Agents adverse effects, Busulfan adverse effects, Busulfan therapeutic use, Clinical Trials as Topic, Female, Humans, Leukemia, Myeloid mortality, Male, Middle Aged, Nitrosourea Compounds adverse effects, Random Allocation, Remission Induction, Antineoplastic Agents therapeutic use, Leukemia, Myeloid drug therapy, Nitrosourea Compounds therapeutic use
Abstract

A new water-soluble nitrosourea derivative, methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU), was found to be useful for the treatment of chronic myelogenous leukemia (CML) in the chronic phase. To compare the efficacy of MCNU with that of busulfan, patients were randomized. In the 40 patients administered MCNU, the median time to the achievement of a complete remission (CR) was 50 days. This value was shorter than that observed in 37 patients administered busulfan (126 days, p less than 0.05). There were no differences in the rate of CR achieved, mortality, median time to the onset of blast crisis (BC), BC rate, or survival rate during the observation period. The overall incidence of side effects was higher for MCNU (31%) than for busulfan (15%), but the symptoms were mild, transient and tolerable for most patients. These results suggest that MCNU is a safe and valuable addition to the therapeutic repertoire for the control of CML.

Published
1988
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results